Mentor Capital Cancer Immunotherapy Index Gains 32% YTD and Adds Second Generation Firms for 2013
SAN DIEGO--(BUSINESS WIRE)-- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that for 2013 it has added Galena Biopharma Corporation (NAS: GALE) , NewLink Genetics Corporation (NAS: NLNK) , Vical Incorporated (NAS: VICL) and Inovio Pharmaceuticals, Inc. (NYSE MKT:INO) to its proprietary Cancer Immunotherapy Index. The four firms and others in the Index represent the second generation immunotherapy knowledge that has evolved since 2009 when Mentor Capital first published.
Year-to-date, the now fifteen Cancer Index members have posted an average 32% gain (161% Annualized). This is more than double the 15% average YTD appreciation of the NASDAQ, S&P, and NYSE Biotech Indices.
The Mentor Capital Cancer Immunotherapy Index companies and their performance for the first ten weeks of 2013 follow: Galena Biopharma Corporation +39.87%, NewLink Genetics Corporation +0.08%, Vical Incorporated +43.30%, Inovio Pharmaceuticals, Inc. +7.65%, Dendreon (NAS: DNDN) +10.40%, Immunocellular Therapeutics, Ltd. (NYSE MKT:IMUC) +40.10%, Agenus (NAS: AGEN) +6.59%, Oncothyreon (NAS: ONTY) +15.63%, Biovest International (Pink Sheets:BVTIQ) -56.00%, Celldex Therapeutics (NAS: CLDX) +78.24%, Northwest Biotherapeutics (NAS: NWBO) +17.96%, CEL - SCI Corp. (NYSE MKT:CVM) -4.44% , Generex Biotechnology (OTCBB:GNBT) +24.00% as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, Provectus Pharmaceuticals, Inc. (Pink Sheets:PVCT) +40.18% and Advaxis, Inc. (OTCBB:ADXS) +199.67% - all for an average 2013 YTD gain of +31.85%. (Annualized rate: 161.48%).
Mentor Capital, Inc., by acquisition or stock purchase, seeks to invest in leading-edge private and public cancer companies, and certain other situations. Mentor created the Cancer Immunotherapy Index July 10, 2009. Since then, it has invested or maintained a tracking position in all companies in the Cancer Immunotherapy Index which can be found at www.MentorCapital.com.
Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.
Mentor Capital, Inc.
Chester Billingsley, CEO
KEYWORDS: United States North America California
The article Mentor Capital Cancer Immunotherapy Index Gains 32% YTD and Adds Second Generation Firms for 2013 originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.